|
||||
|
Product trade name: Deaten
Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products: Deaten available forms, composition, doses: Deaten destination | category: Indications and usages, anatomical therapeutic chemical and diseases classification codes: Pharmaceutical companies, researchers, developers, manufacturers, distributors and suppliers: Online pharmacy, drugstores, pharma, health and beauty shops selling this or related pharmaceutical products: There is an additional general information about this medication active ingredient atomoxetine: Pharmacological action Deaten is a centrally acting sympathomimetic. This medication is highly selective potent inhibitor of presynaptic norepinephrine transporters. Atomoxetine has minimal affinity to the other noradrenergic receptors or to other transporters or receptors of neurotransmitters. This drug does not apply to psychostimulants and it is not a derivative of amphetamine. In clinical trials there were not noted of increase symptoms or any adverse events associated with withdrawal syndrome. Pharmacokinetics After oral administration Deaten is quickly and almost completely absorbed, reaching a Cmax in the plasma of approximately 1-2 hours. This medication is well distributed in the body. It has a high affinity for plasma proteins, primarily to albumin. The average T1/2 of atomoxetine after oral administration is 3.6 hours in patients with severe metabolism and 21 hours in patients with decreased metabolism. This drug is mainly excreted in the urine. Why is Deaten prescribed? Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years and older, adolescents and adults. Dosage and administration Deaten is taken orally regardless of the meal or during a meal, as a single daily dose in the morning. In the case of adverse reactions while taking the drug 1 time / day, patients can be recommended to receive doses 2 times / day, dividing the dose by levee and reception late in the afternoon or early evening. For children and adolescents weighing 70 kg the recommended initial daily dose is about 0.5 mg / kg and increased to a therapeutic daily dose of about 1.2 mg / kg no sooner than 3 days. In the absence of improvement of the patient's total daily dose may be increased to a maximum dose of 1.8 mg / kg no sooner than 2-4 weeks after starting treatment. The recommended maintenance dose is approximately 1.2 mg / kg / day. The recommended maximum daily dose is 1.8 mg / kg or 120 mg. For children and adolescents weighing over 70 kg and adults the recommended initial daily dose is 40 mg and increased to a therapeutic daily dose of 80 mg no earlier than 3 days. In the absence of improvement of the patient's total daily dose may be increased to a maximum dose of 120 mg did not earlier than 2-4 weeks after starting treatment. The recommended maintenance dose is 80 mg. The recommended maximum daily dose is 120 mg. Deaten side effects, adverse reactions Side effects in patients with poor metabolism: loss of appetite, insomnia, impaired quality of sleep, enuresis, poor mood, tremor, early morning awakening, conjunctivitis, syncope, mydriasis. Digestive system: very often - loss of appetite, dry mouth, nausea; often - abdominal pain, constipation, dyspepsia, flatulence. CNS: very often - insomnia; often - early morning awakening, decreased libido, insomnia, dizziness, impaired sleep quality, sinus headache, drowsiness. Cardiovascular system: often - hot flashes of blood, palpitations, tachycardia; sometimes - the feeling of coldness in the lower extremities; very rare - peripheral vascular reactions and / or Raynaud's syndrome and Raynaud's syndrome risk of relapse. Urinary system: often - difficulty urinating, urinary retention. Reproductive system: often - dysmenorrhea, abnormal ejaculation, lack of ejaculation, erectile dysfunction, erectile dysfunction, menstrual disorders, impaired orgasm, prostate; very rare - according to spontaneous reports, a painful or prolonged erection. Dermatological reactions: often - dermatitis, excessive sweating. Other: often - fatigue, chills, weight loss. Deaten contraindications The simultaneous use of MAO inhibitors, angle-closure glaucoma, increased sensitivity to atomoxetine. Using during pregnancy and breastfeeding The use of Deaten pregnancy and lactation is possible only if the expected benefit of therapy to the mother far outweighs the potential risk to the fetus or infant. It is not known whether atomoxetine excreted in breast milk in humans. Special instructions Use Deaten with caution in patients with hypertension, tachycardia, with cardiovascular disease, violation of cerebral circulation, as well as any condition which may lead to hypotension, since reported cases of orthostatic hypotension. This medication can cause arterial hypertension in patients with end-stage renal disease. ADHD symptoms as impaired attention and hyperactivity may been showed as impairment of concentration, distractibility, excessive restlessness, impulsiveness, disorganization, restlessness, and other similar conduct disorder. The diagnosis of ADHD must meet the criteria for ICD-10. In clinical studies in children and adolescents during treatment with this medicine there was increased a risk of suicidal thoughts. In rare cases, patients taking Deaten observed allergic reactions - rashes, angioedema, urticaria. This drug should not be used for at least 2 weeks after discontinuation of MAO inhibitors. Treatment of MAO inhibitors should not be initiated within 2 weeks after discontinuation of atomoxetine. Many patients taking atomoksetin, there was some increase in heart rate (an average of < 10 beats / min) and / or increased blood pressure (an average of < 5 mm Hg). In most cases, these changes were not clinically significant effect. Also there were cases of orthostatic hypotension. In patients with manifestations of jaundice or laboratory parameters identified which indicate liver dysfunction this medication should be abolished. Patients (especially children and teenagers) who are receiving treatment for ADHD should be monitored for the onset of aggressive behavior or hostility. Patients receiving Deaten require supervision due to risk of occurrence of the following symptoms: anxiety, agitation, panic attacks, insomnia, irritability, impulsivity, akathisia, hypomania and mania. Deaten drug interactions When this drug applied simultaneously with agonists of beta2-adrenergic receptors it may been increase their effects on the cardiovascular system (this combination should be used with caution). In patients with severe metabolism CYP2D6 inhibitors increase the content of CYP2D6 atomoxetine in plasma at steady state to a level similar to that in patients with decreased metabolism of CYP2D6. When Deaten used with drugs affecting blood pressure it may been changes in blood pressure. Deaten in case of emergency / overdose Symptoms: drowsiness, agitation, hyperactivity, behavioral disorders, gastrointestinal dysfunction, mydriasis, tachycardia, dry mouth, seizures. Treatment: gastric lavage, activated charcoal, control of the heart and vital signs, ventilation, symptomatic and supportive therapy. Hemodialysis is ineffective.
Comments
|
|
|||
|
||||